RGD胜肽市场按应用、最终用途、类型、形式和分子量划分，全球预测（2026-2032年）

RGD胜肽市场预计到2025年将达到2.6848亿美元，到2026年将成长到2.9955亿美元，到2032年将达到5.2545亿美元，复合年增长率为10.06%。

关键市场统计数据
基准年 2025	2.6848亿美元
预计年份：2026年	2.9955亿美元
预测年份 2032	5.2545亿美元
复合年增长率 (%)	10.06%

本书权威地介绍了RGD胜肽的生化作用、关键的转化联繫，以及为何相关人员应优先考虑对其策略理解。

本报告对RGD胜肽进行了清晰权威的阐述，介绍了其在细胞黏附中的生化作用，以及其对研究和商业应用的重要策略意义。 RGD胜肽是由整合素受体辨识的短胺基酸序列，是细胞-基质相互作用的重要介质，并在研究分析和生物医学应用解决方案中发挥模组化配体的作用。理解RGD基序的基本生物学特性至关重要，因为其相互作用的动态变化会影响分析设计、表面修饰、标靶递送系统以及组织支架的表现。

关键的技术、监管和供应链力量正在汇聚，重塑 RGD 胜肽在多学科领域的开发、检验和商业化。

胜肽工程、表面科学和转化生物学领域的融合进展正在加速从发现到应用的进程，并改变RGD肽的模式。化学选择性合成技术的进步，包括改进的环化方法和位点特异性修饰，提高了配体的稳定性和整合素选择性，在体外实验和装置介面中实现了更可靠的性能。同时，高解析度质谱和表面等离子体共振等分析表征技术的进步，增强了人们对结构-功能关係的信心，并使研究团队能够更快地迭代设计，减少实验次数。

评估不断变化的美国关税措施对胜肽类药物研发领域的采购、供应商策略和业务永续营运的影响

近期贸易政策的变化给依赖国际采购原料、契约製造和实验室试剂的企业带来了新的成本和营运方面的挑战。关税措施及相关的非关税应对措施会改变供应商的经济状况，迫使采购方重新评估供应商合格框架，并要求制定入境物流紧急时应对计画，从而增加采购营运的复杂性。在依赖胜肽的工作流程中，试剂纯度和批次间性能的一致性至关重要，即使是轻微的干扰和成本波动也可能导致检验工作量增加，并延长检测方法验证和设备开发时间。

透过综合分析应用需求、最终用途要求、分子类型、供应形式和分子量等因素，为策略决策提供支援。

分段观点突显了技术需求与商业性优先事项的分歧领域，以及能够带来最大回报的定向投资领域。纵观细胞黏附研究、诊断检测、药物递送、医疗设备涂层和组织工程等多种应用，每种应用场景都提出了独特的性能和监管要求，这些要求会影响胜肽的设计方案和检验路径。细胞黏附实验强调可重复性和表面呈现，而诊断检测则优先考虑特异性和批间一致性。药物递送应用需要控释和生物稳定性，而器械涂层则要求耐久性和符合监管要求的生物相容性。组织工程应用则着重于支架整合和长期细胞反应。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和驱动因素将影响RGD胜肽相关计划的采纳、采购和监管协调。

区域趋势在塑造胜肽类技术的监管要求、供应商生态系统和应用路径方面发挥着至关重要的作用。在美洲，成熟的研究基础设施、广泛的合约组织网路以及开放的商业生态系统促进了早期应用，并推动了开发商和买家之间的密切合作。监管和津贴计画也支持转化研究，从而加速从概念验证研究到临床试验材料的转化。

竞争格局与企业趋势：建立专业知识、伙伴关係和品质能力将如何重新定义胜肽解决方案领域的领导地位

胜肽领域的企业活动呈现出专业化、策略联盟和多层次能力并存的特征。胜肽合成专家正致力于投资基础化学和品质体系，以提高重现性并降低杂质含量；而诊断和医疗设备公司则将胜肽专业知识整合到更广泛的产品系列中，以增强表面功能和标靶化能力。合约开发和生产组织（CDMO）正在拓展其服务范围，包括法规支援、分析开发和可扩展的胜肽生产，以满足早期开发商和大规模商业合作伙伴的需求。

为领导者提供切实可行的优先步骤，以增强韧性、优化发展路径，并将RGD胜肽创新成果快速转化为应用解决方案。

为了将科学优势转化为永续的商业性和营运成果，领导者应优先采取一系列切实可行的措施，使技术能力与供应链韧性和监管准备保持一致。首先，将可製造性和供应商选择纳入早期开发规划，使胜肽设计从一开始就考虑规模限制和品质规格。这可以减少后续迭代，并有助于在产品过渡到受监管环境时进行验证。其次，实现供应商关係的地理多元化，并至少认证一个关键投入的区域供应商，以降低贸易政策和物流中断的影响。

一份透明的调查方法说明，清楚地概述了文献综述、专家对话、分析框架和检验方法，以支持报告的结论。

研究途径结合了对同侪审查文献、技术白皮书和已发布的监管指南的系统性回顾，以及对专家和从业人员的定性访谈。我们利用二手资料梳理了胜肽化学、分析方法和供应链结构的历史发展趋势，并透过访谈深入了解了采购行为、检验重点和风险管理实务等方面的背景资讯。分析架构包括一项比较技术评估，用于评估环状、线性和修饰RGD结构之间的设计权衡；以及一项供应链映射，用于识别单一来源的薄弱环节和区域优势。

透过对科学进展、实际操作情况和政策因素进行综合分析，可以为参与胜肽类药物主导措施的相关人员提供清晰的策略启示。

这项综合分析凸显了一个明确的需求：将RGD胜肽已证实的生物效用转化为可靠、符合法规且具有商业性可行性的应用，需要化学、分析、供应链和法规规划等各环节的协调投资。儘管胜肽设计方面的科学进步降低了稳定性和特异性方面的传统障碍，但供应商选择标准、区域法规差异以及贸易相关波动等营运和政策因素，如今对专案执行进度和风险状况的影响却不成比例地更大。能够将技术选择与切实可行的采购、品质和法规策略相结合的企业将取得最大的成功。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席主管观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 上市策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. RGD肽市场依应用领域划分

• 细胞黏附研究
• 诊断检测
• 药物递送
• 医疗设备涂层
• 组织工程

9. RGD肽市场依最终用途划分

• 学术研究
• 生物技术
• 诊断
• 製药

第十章：RGD胜肽市场（按类型划分）

• 圆
• 线性类型
• 合格类型

第十一章：RGD胜肽市场（依形式划分）

• 冻干产品
• 粉末
• 解决方案

12. RGD肽市场（以分子量划分）

• 高分子量
• 低分子量
• 中等分子量

第十三章：RGD胜肽市场区域分析

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 RGD胜肽市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国RGD胜肽市场

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章：美国RGD胜肽市场

第十七章：中国的RGD胜肽市场

第十八章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• AmbioPharm, Inc.
• AnaSpec Inc.
• Bachem Holding AG
• Bio-Synthesis, Inc.
• Biomatik Corporation
• Biotage AB
• CEM Corporation
• Corden Pharma GmbH
• CPC Scientific Inc.
• Creative Peptides
• CSBio Company, Inc.
• GenScript Biotech Corporation
• GL Biochem（Shanghai）Ltd.
• Hybio Pharmaceutical Co. Ltd.
• JPT Peptide Technologies
• Merck KGaA
• New England Peptide, Inc.
• Peptides International, LLC
• PolyPeptide Group
• ProteoGenix
• Scilight-Peptide Inc.
• SynPeptide Co., Ltd.
• Thermo Fisher Scientific Inc.
• USV Private Limited
• WuXi AppTec

The RGD Peptide Market was valued at USD 268.48 million in 2025 and is projected to grow to USD 299.55 million in 2026, with a CAGR of 10.06%, reaching USD 525.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 268.48 million
Estimated Year [2026]	USD 299.55 million
Forecast Year [2032]	USD 525.45 million
CAGR (%)	10.06%

An authoritative primer explaining the biochemical role of RGD peptides, key translational linkages, and why stakeholders should prioritize strategic understanding

This executive dossier provides a clear and authoritative orientation to RGD peptides, their biochemical role in cell adhesion, and their strategic relevance across research and commercial domains. RGD peptides are short amino acid sequences recognized by integrin receptors, serving as key mediators of cell-matrix interactions and functioning as modular ligands in both investigative assays and applied biomedical solutions. Understanding the fundamental biology of RGD motifs is essential because their interaction dynamics influence assay design, surface engineering, targeted delivery systems, and tissue scaffold performance.

Beyond molecular function, RGD peptides occupy a unique translational nexus where basic science informs applied engineering and clinical development. Their utility spans laboratory-focused cell adhesion models, diagnostic assay platforms that exploit integrin binding, and biomedical product coatings that modulate host responses. The introduction sets the stage for a deeper review by clarifying terminology, delineating principal applications, and framing the consequential linkages between scientific advances and operational considerations that follow in subsequent sections.

Key technological, regulatory, and supply chain forces converging to reshape how RGD peptides are developed, validated, and commercialized across disciplines

The RGD peptide landscape is being transformed by convergent advances in peptide engineering, surface science, and translational biology that are accelerating the pace from discovery to applied use. Advances in chemoselective synthesis, including improved methods for cyclization and site-specific modification, have enhanced ligand stability and integrin selectivity, enabling more reliable performance in both in vitro assays and device interfaces. Concurrent improvements in analytical characterization-high-resolution mass spectrometry and surface plasmon resonance-have increased confidence in structure-function relationships, allowing teams to iterate designs more rapidly and with fewer experimental cycles.

At the same time, cross-disciplinary pressures are reshaping adoption pathways. Regulatory authorities are placing greater emphasis on biocompatibility testing and transparency in sourcing, which is prompting earlier incorporation of manufacturability and regulatory alignment into development plans. Meanwhile, the proliferation of contract development and manufacturing partnerships is enabling smaller innovators to scale peptide-enabled solutions without extensive in-house infrastructure. Taken together, these technological and structural shifts are driving a landscape where scientific rigor, supply chain maturity, and regulatory foresight determine the speed and success of translation from bench to application.

Evaluating how evolving United States tariff measures can affect procurement, supplier strategies, and operational continuity for peptide-dependent research and development

Recent trade policy dynamics have introduced new cost and operational considerations for organizations that rely on internationally sourced raw materials, contract manufacturing, and laboratory reagents. Tariff measures and associated non-tariff responses can amplify procurement complexity by altering supplier economics, forcing buyers to re-evaluate supplier qualification frameworks, and requiring contingency planning for inbound logistics. For peptide-dependent workflows, where reagent purity and consistent lot-to-lot performance are critical, even modest disruptions or cost variances can translate into increased validation burdens and extended timelines for assay qualification and device development.

In response, many stakeholders are adapting sourcing strategies to mitigate exposure and preserve program momentum. Tactical responses include diversifying supplier networks across geographies, prioritizing qualified domestic or regional suppliers for critical inputs, and increasing inventory buffers for long-lead items. Process optimization and closer collaboration with suppliers on quality systems can reduce the operational friction introduced by tariff-induced supplier changes. Overall, the cumulative effect of tariff-driven disruptions emphasizes the importance of supply chain visibility, flexible procurement policies, and early supplier engagement to maintain continuity in research and product development activities.

Integrated segmentation analysis connecting application needs, end-use requirements, molecular types, supply formats, and molecular weight considerations to inform strategic decisions

A segmentation-informed perspective clarifies where technical needs and commercial priorities diverge and where targeted investments will yield the highest return. When looking across applications such as cell adhesion studies, diagnostic assays, drug delivery, medical device coatings, and tissue engineering, each use case imposes distinct performance and regulatory requirements that influence peptide design choices and validation pathways. Cell adhesion experiments emphasize reproducibility and surface presentation, diagnostic assays prioritize specificity and batch consistency, drug delivery applications require controlled release and biostability, device coatings demand durability and regulatory-grade biocompatibility, and tissue engineering applications focus on scaffold integration and long-term cellular responses.

End-use contexts including academic research, biotechnology, diagnostic, and pharmaceutical settings further shape priorities around documentation, lot traceability, and supply continuity. From a product-type perspective, cyclic, linear, and modified RGD constructs offer trade-offs between conformational stability and synthetic tractability, guiding selection based on intended function. The physical form of supply-whether lyophilized, powder, or solution-affects shelf life, shipping constraints, and downstream handling, while molecular weight distinctions among high, medium, and low molecular weight variants inform diffusion behavior, surface density considerations, and pharmacokinetic expectations. Synthesizing these dimensions highlights how technical, regulatory, and operational vectors must be aligned to match the right peptide configuration to its target application and stakeholder requirements.

Regional dynamics and enablers across Americas, Europe, Middle East & Africa, and Asia-Pacific that influence adoption, sourcing, and regulatory alignment for RGD peptide initiatives

Regional dynamics play a decisive role in shaping regulatory expectations, supplier ecosystems, and adoption trajectories for peptide-enabled technologies. In the Americas, a mature research infrastructure, a deep network of contract organizations, and a receptive commercial ecosystem drive early adoption and close collaboration between developers and purchasers. Regulatory agencies and grant mechanisms also support translational initiatives that can accelerate the movement from proof-of-concept work to clinical trial material.

Across Europe, the Middle East & Africa, regulatory harmonization efforts and strong academic-industrial partnerships foster rigorous evaluation of biocompatibility and safety, while localized manufacturing hubs contribute to resilient supply chains. In the Asia-Pacific region, rapid scale-up capabilities, competitive manufacturing, and robust reagent supply networks offer cost and capacity advantages, although stakeholders must navigate diverse regulatory pathways and varying standards for clinical translation. Understanding these regional attributes enables organizations to calibrate sourcing strategies, select appropriate regulatory engagement approaches, and identify strategic partners to support both immediate project needs and longer-term commercialization pathways.

Competitive landscape and corporate dynamics revealing how specialization, partnerships, and quality capability buildouts are redefining leadership in peptide solutions

Corporate activity in the peptide domain is characterized by a mix of specialization, strategic partnerships, and capability layering. Companies focused on peptide synthesis have invested in platform chemistries and quality systems to improve reproducibility and reduce impurity profiles, while diagnostic and device-oriented firms are integrating peptide expertise into broader product portfolios to enhance surface functionality and targeting. Contract development and manufacturing organizations are expanding services to include regulatory support, analytical development, and scalable peptide production to meet the needs of both early-stage developers and larger commercial partners.

Collaboration models-ranging from co-development agreements to manufacturing partnerships-are increasingly preferred over solitary approaches, as they enable sharing of risk and faster access to complementary capabilities. Investment in specialized analytical capacity and robust quality management systems signals which organizations are best positioned to supply regulated applications. For stakeholders selecting partners, emphasis should be placed on demonstrated technical depth, transparent quality evidence, and the ability to support lifecycle activities beyond initial supply, such as stability studies, change control, and regulatory documentation.

Practical, prioritized steps for leaders to strengthen resilience, optimize development pathways, and accelerate translation of RGD peptide innovations into applied solutions

To convert scientific advantage into durable commercial and operational outcomes, leaders should prioritize a set of practical actions that align technical performance with supply chain resilience and regulatory readiness. First, integrate manufacturability and supplier qualification into early development planning so peptide designs account for scale constraints and quality specifications from the outset. This reduces iteration later and facilitates smoother validation when moving to regulated contexts. Second, diversify supplier relationships geographically while qualifying at least one regional source for critical inputs to mitigate trade-policy and logistical disruptions.

Third, invest in analytical and process characterization capabilities that enable rapid troubleshooting and reduce batch variability, complemented by transparent documentation practices that meet the expectations of diagnostic and pharmaceutical end users. Fourth, pursue strategic collaborations with contract organizations or academic partners to access specialized capabilities without the full capital investment of in-house expansion. Finally, embed regulatory strategy into program timelines, engaging with relevant authorities or notified bodies early to clarify biocompatibility expectations and streamline downstream approvals. Taken together, these actions strengthen resilience and accelerate the translation of RGD-enabled innovations into practice.

Transparent methodological description outlining literature synthesis, expert engagement, analytical frameworks, and validation practices that underpin the report's conclusions

The research approach combined a structured review of peer-reviewed literature, technical white papers, and publicly available regulatory guidance with primary qualitative interviews of domain experts and practitioners. Secondary sources were used to map historical trends in peptide chemistry, analytical practices, and supply chain configurations, while primary interviews provided contextual nuance on procurement behavior, validation priorities, and risk management approaches. Analytical frameworks included comparative technology assessment to evaluate design trade-offs among cyclic, linear, and modified RGD constructs and supply chain mapping to identify single-source vulnerabilities and regional strengths.

Data validation incorporated cross-referencing of interview insights against published experimental protocols and internal quality documents provided during engagement with consenting organizations. The methodological emphasis on triangulation and traceable evidence ensures that conclusions are supported by multiple independent lines of inquiry. Limitations are acknowledged where proprietary or nascent commercial data were unavailable, and recommendations are framed to be robust to variability in organizational scale and regulatory jurisdictional differences.

Concluding synthesis that connects scientific progress, operational realities, and policy factors to provide clear strategic takeaways for stakeholders in peptide-driven initiatives

The synthesis underscores a clear imperative: translating the proven biological utility of RGD peptides into reliable, regulated, and commercially viable applications requires coordinated investments across chemistry, analytics, supply chain, and regulatory planning. Scientific advances in peptide design have reduced historical barriers related to stability and specificity, but operational and policy variables - including supplier qualification, regional regulatory nuance, and trade-related volatility - now exert outsized influence on execution timelines and program risk profiles. Successful actors will be those who align technical choices with pragmatic sourcing, quality, and regulatory strategies.

Ultimately, the path forward favors interdisciplinary collaboration, early engagement with manufacturing and regulatory partners, and disciplined attention to analytical characterization and documentation. By aligning these elements with a clear segmentation and regional strategy, organizations can better position RGD peptide-enabled solutions for robust performance in both research and applied settings and reduce avoidable delays during critical development transitions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RGD Peptide Market, by Application

• 8.1. Cell Adhesion Studies
• 8.2. Diagnostic Assays
• 8.3. Drug Delivery
• 8.4. Medical Device Coatings
• 8.5. Tissue Engineering

9. RGD Peptide Market, by End Use

• 9.1. Academic Research
• 9.2. Biotechnology
• 9.3. Diagnostic
• 9.4. Pharmaceutical

10. RGD Peptide Market, by Type

• 10.1. Cyclic
• 10.2. Linear
• 10.3. Modified

11. RGD Peptide Market, by Form

• 11.1. Lyophilized
• 11.2. Powder
• 11.3. Solution

12. RGD Peptide Market, by Molecular Weight

• 12.1. High Molecular Weight
• 12.2. Low Molecular Weight
• 12.3. Medium Molecular Weight

13. RGD Peptide Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. RGD Peptide Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. RGD Peptide Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States RGD Peptide Market

17. China RGD Peptide Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. AmbioPharm, Inc.
• 18.6. AnaSpec Inc.
• 18.7. Bachem Holding AG
• 18.8. Bio-Synthesis, Inc.
• 18.9. Biomatik Corporation
• 18.10. Biotage AB
• 18.11. CEM Corporation
• 18.12. Corden Pharma GmbH
• 18.13. CPC Scientific Inc.
• 18.14. Creative Peptides
• 18.15. CSBio Company, Inc.
• 18.16. GenScript Biotech Corporation
• 18.17. GL Biochem (Shanghai) Ltd.
• 18.18. Hybio Pharmaceutical Co. Ltd.
• 18.19. JPT Peptide Technologies
• 18.20. Merck KGaA
• 18.21. New England Peptide, Inc.
• 18.22. Peptides International, LLC
• 18.23. PolyPeptide Group
• 18.24. ProteoGenix
• 18.25. Scilight-Peptide Inc.
• 18.26. SynPeptide Co., Ltd.
• 18.27. Thermo Fisher Scientific Inc.
• 18.28. USV Private Limited
• 18.29. WuXi AppTec

LIST OF FIGURES

• FIGURE 1. GLOBAL RGD PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL RGD PEPTIDE MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL RGD PEPTIDE MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL RGD PEPTIDE MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL RGD PEPTIDE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL RGD PEPTIDE MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL RGD PEPTIDE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL RGD PEPTIDE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES RGD PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA RGD PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL RGD PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL RGD PEPTIDE MARKET SIZE, BY CELL ADHESION STUDIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL RGD PEPTIDE MARKET SIZE, BY CELL ADHESION STUDIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL RGD PEPTIDE MARKET SIZE, BY CELL ADHESION STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL RGD PEPTIDE MARKET SIZE, BY DIAGNOSTIC ASSAYS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL RGD PEPTIDE MARKET SIZE, BY DIAGNOSTIC ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL RGD PEPTIDE MARKET SIZE, BY DIAGNOSTIC ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL RGD PEPTIDE MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL RGD PEPTIDE MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL RGD PEPTIDE MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL RGD PEPTIDE MARKET SIZE, BY MEDICAL DEVICE COATINGS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL RGD PEPTIDE MARKET SIZE, BY MEDICAL DEVICE COATINGS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL RGD PEPTIDE MARKET SIZE, BY MEDICAL DEVICE COATINGS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL RGD PEPTIDE MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL RGD PEPTIDE MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL RGD PEPTIDE MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL RGD PEPTIDE MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL RGD PEPTIDE MARKET SIZE, BY ACADEMIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL RGD PEPTIDE MARKET SIZE, BY ACADEMIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL RGD PEPTIDE MARKET SIZE, BY BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL RGD PEPTIDE MARKET SIZE, BY BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL RGD PEPTIDE MARKET SIZE, BY BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL RGD PEPTIDE MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL RGD PEPTIDE MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL RGD PEPTIDE MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL RGD PEPTIDE MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL RGD PEPTIDE MARKET SIZE, BY PHARMACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL RGD PEPTIDE MARKET SIZE, BY PHARMACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL RGD PEPTIDE MARKET SIZE, BY CYCLIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL RGD PEPTIDE MARKET SIZE, BY CYCLIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL RGD PEPTIDE MARKET SIZE, BY CYCLIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL RGD PEPTIDE MARKET SIZE, BY LINEAR, BY REGION, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL RGD PEPTIDE MARKET SIZE, BY LINEAR, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL RGD PEPTIDE MARKET SIZE, BY LINEAR, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL RGD PEPTIDE MARKET SIZE, BY MODIFIED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL RGD PEPTIDE MARKET SIZE, BY MODIFIED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL RGD PEPTIDE MARKET SIZE, BY MODIFIED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL RGD PEPTIDE MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL RGD PEPTIDE MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL RGD PEPTIDE MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL RGD PEPTIDE MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL RGD PEPTIDE MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL RGD PEPTIDE MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL RGD PEPTIDE MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL RGD PEPTIDE MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL RGD PEPTIDE MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL RGD PEPTIDE MARKET SIZE, BY HIGH MOLECULAR WEIGHT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL RGD PEPTIDE MARKET SIZE, BY HIGH MOLECULAR WEIGHT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL RGD PEPTIDE MARKET SIZE, BY HIGH MOLECULAR WEIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL RGD PEPTIDE MARKET SIZE, BY LOW MOLECULAR WEIGHT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL RGD PEPTIDE MARKET SIZE, BY LOW MOLECULAR WEIGHT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL RGD PEPTIDE MARKET SIZE, BY LOW MOLECULAR WEIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL RGD PEPTIDE MARKET SIZE, BY MEDIUM MOLECULAR WEIGHT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL RGD PEPTIDE MARKET SIZE, BY MEDIUM MOLECULAR WEIGHT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL RGD PEPTIDE MARKET SIZE, BY MEDIUM MOLECULAR WEIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL RGD PEPTIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 62. AMERICAS RGD PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 63. AMERICAS RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 64. AMERICAS RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 65. AMERICAS RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 66. AMERICAS RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 67. AMERICAS RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 68. NORTH AMERICA RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. NORTH AMERICA RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 70. NORTH AMERICA RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 71. NORTH AMERICA RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 72. NORTH AMERICA RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 73. NORTH AMERICA RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 74. LATIN AMERICA RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. LATIN AMERICA RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 76. LATIN AMERICA RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 77. LATIN AMERICA RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 78. LATIN AMERICA RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 79. LATIN AMERICA RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA RGD PEPTIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 86. EUROPE RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 87. EUROPE RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 88. EUROPE RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 89. EUROPE RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 90. EUROPE RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 91. EUROPE RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 92. MIDDLE EAST RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 93. MIDDLE EAST RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 94. MIDDLE EAST RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 95. MIDDLE EAST RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 96. MIDDLE EAST RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 97. MIDDLE EAST RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 98. AFRICA RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. AFRICA RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 100. AFRICA RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 101. AFRICA RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 102. AFRICA RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 103. AFRICA RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 104. ASIA-PACIFIC RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 105. ASIA-PACIFIC RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 106. ASIA-PACIFIC RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 107. ASIA-PACIFIC RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 108. ASIA-PACIFIC RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 109. ASIA-PACIFIC RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 110. GLOBAL RGD PEPTIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 111. ASEAN RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 112. ASEAN RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 113. ASEAN RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 114. ASEAN RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 115. ASEAN RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 116. ASEAN RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 117. GCC RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 118. GCC RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 119. GCC RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 120. GCC RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 121. GCC RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 122. GCC RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 123. EUROPEAN UNION RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 124. EUROPEAN UNION RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 125. EUROPEAN UNION RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 126. EUROPEAN UNION RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 127. EUROPEAN UNION RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 128. EUROPEAN UNION RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 129. BRICS RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 130. BRICS RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 131. BRICS RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 132. BRICS RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 133. BRICS RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 134. BRICS RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 135. G7 RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 136. G7 RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 137. G7 RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 138. G7 RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 139. G7 RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 140. G7 RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 141. NATO RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 142. NATO RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 143. NATO RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 144. NATO RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 145. NATO RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 146. NATO RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 147. GLOBAL RGD PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 148. UNITED STATES RGD PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 149. UNITED STATES RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 150. UNITED STATES RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 151. UNITED STATES RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 152. UNITED STATES RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 153. UNITED STATES RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)
• TABLE 154. CHINA RGD PEPTIDE MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 155. CHINA RGD PEPTIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
• TABLE 156. CHINA RGD PEPTIDE MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
• TABLE 157. CHINA RGD PEPTIDE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
• TABLE 158. CHINA RGD PEPTIDE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
• TABLE 159. CHINA RGD PEPTIDE MARKET SIZE, BY MOLECULAR WEIGHT, 2018-2032 (USD MILLION)